T. Rowe Price Associates Portfolio holdings
T. Rowe Price Associates, Inc., founded in 1937 by Thomas Rowe Price, Jr., is a globally recognized investment management firm headquartered in Baltimore, Maryland, known for its disciplined, research-driven approach to active investing. The company manages hundreds of billions in assets, offering a wide range of mutual funds, retirement plans, and advisory services tailored to individual investors, institutions, and financial intermediaries. Emphasizing long-term growth and a conservative investment philosophy, T. Rowe Price has built a strong reputation for its equity and fixed-income funds, often focusing on fundamental analysis to identify undervalued opportunities. Still publicly traded and independent, it remains a trusted name in the industry, balancing tradition with innovation to meet evolving client needs.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Lam Research
LRCX
|
+$1.66B |
| 2 |
KLA
KLAC
|
+$1.39B |
| 3 |
T-Mobile US
TMUS
|
+$1.38B |
| 4 |
Eli Lilly
LLY
|
+$1.37B |
| 5 |
CSX Corp
CSX
|
+$1.18B |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
NVIDIA
NVDA
|
+$4.2B |
| 2 |
Microsoft
MSFT
|
+$3.24B |
| 3 |
Amazon
AMZN
|
+$2.75B |
| 4 |
Netflix
NFLX
|
+$2.53B |
| 5 |
Apple
AAPL
|
+$2.48B |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 35.66% |
| 2 | Financials | 11.78% |
| 3 | Healthcare | 11.44% |
| 4 | Consumer Discretionary | 10.75% |
| 5 | Communication Services | 10.73% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1751
Stock Yards Bancorp
SYBT
$2.65B
| $1.95M | ﹤0.01% |
30,003
+1,951
| +7% | +$131K |
|
1752
First Commonwealth Financial
FCF
$2.19B
| $1.95M | ﹤0.01% |
115,515
+6,036
| +6% | +$99K |
|
1753
Sarepta Therapeutics
SRPT
$1.89B
| $1.94M | ﹤0.01% |
90,038
+11
| +0% | +$232 |
|
1754
Arcos Dorados Holdings
ARCO
$1.69B
| $1.93M | ﹤0.01% |
263,307
| – | – |
|
1755
10x Genomics
TXG
$7.38B
| $1.93M | ﹤0.01% |
118,371
-34,459
| -23% | -$521K |
|
1756
Pagaya Technologies
PGY
$1.79B
| $1.93M | ﹤0.01% |
92,297
-211,360
| -70% | -$5.38M |
|
1757
Yelp
YELP
$1.33B
| $1.93M | ﹤0.01% |
63,360
+4,050
| +7% | +$125K |
|
1758
Stewart Information Services
STC
$2.07B
| $1.92M | ﹤0.01% |
27,378
+1,337
| +5% | +$96.3K |
|
1759
Harley-Davidson
HOG
$2.89B
| $1.92M | ﹤0.01% |
93,735
+7,759
| +9% | +$191K |
|
1760
NETSCOUT
NTCT
$2.88B
| $1.92M | ﹤0.01% |
70,967
+3,006
| +4% | +$81.3K |
|
1761
Cedar Fair
FUN
$1.7B
| $1.91M | ﹤0.01% |
124,708
-6,886
| -5% | -$125K |
|
1762
Kennametal
KMT
$2.37B
| $1.91M | ﹤0.01% |
67,305
+2,923
| +5% | +$74.7K |
|
1763
iShares S&P Mid-Cap 400 Growth ETF
IJK
$11.3B
| $1.91M | ﹤0.01% |
19,700
+7,225
| +58% | +$696K |
|
1764
1st Source
SRCE
$2.14B
| $1.91M | ﹤0.01% |
30,509
+981
| +3% | +$60.7K |
|
1765
NuScale Power
SMR
$3.94B
| $1.91M | ﹤0.01% |
134,469
+18,960
| +16% | +$542K |
|
1766
La-Z-Boy
LZB
$1.67B
| $1.91M | ﹤0.01% |
51,087
+2,315
| +5% | +$81.1K |
|
1767
AtaiBeckley Inc
ATAI
$2.69B
| $1.9M | ﹤0.01% |
+465,352
| New | +$2.2M |
|
1768
Quantum Computing Inc
QUBT
$2.02B
| $1.9M | ﹤0.01% |
184,772
+87,383
| +90% | +$1.24M |
|
1769
Atour Lifestyle Holdings
ATAT
$4.61B
| $1.9M | ﹤0.01% |
48,083
-3,439
| -7% | -$135K |
|
1770
Credit Acceptance
CACC
$6.1B
| $1.9M | ﹤0.01% |
4,272
+158
| +4% | +$73.2K |
|
1771
PENN Entertainment
PENN
$2.52B
| $1.89M | ﹤0.01% |
128,296
+3,444
| +3% | +$53.7K |
|
1772
InvenTrust Properties
IVT
$2.63B
| $1.88M | ﹤0.01% |
66,530
+2,502
| +4% | +$70.5K |
|
1773
Opendoor
OPEN
$3.5B
| $1.87M | ﹤0.01% |
321,374
-27,976
| -8% | -$200K |
|
1774
International Seaways
INSW
$4.75B
| $1.87M | ﹤0.01% |
38,540
+1,560
| +4% | +$77.2K |
|
1775
Twist Bioscience
TWST
$7.51B
| $1.87M | ﹤0.01% |
58,985
+5,135
| +10% | +$160K |
|
Similar funds
T. Rowe Price Associates's Q4 2025 Portfolio in Review
As of Q4 2025, T. Rowe Price Associates held 3,154 positions worth $927B, down 0.78% from $935B the previous quarter. Its ten largest holdings account for 37% of the portfolio.
T. Rowe Price Associates's Q4 2025 filing shows 113 new, 1,841 increased, 860 reduced and 65 closed positions. Its largest new stake was Medline Inc: 7,325,104 shares worth $308M. The largest sale was NVIDIA, an estimated $4.2B.
By sector, the portfolio is most concentrated in Technology at 36% of assets, down from 36% a quarter earlier, followed by Financials and Healthcare.
- T. Rowe Price Associates's largest Q4 2025 buy was Medline Inc: 7,325,104 shares worth $308M.
- T. Rowe Price Associates added most to Lam Research in Q4 2025, an estimated $1.66B increase.
- T. Rowe Price Associates's biggest Q4 2025 reduction was NVIDIA, cutting an estimated $4.2B.
- T. Rowe Price Associates fully exited Akero Therapeutics in Q4 2025, selling an estimated $181M.
- T. Rowe Price Associates's ten largest holdings make up 37% of its $927B portfolio in Q4 2025.
- T. Rowe Price Associates opened 113 new positions and closed 65 in Q4 2025.
- T. Rowe Price Associates's portfolio value fell 0.78% quarter-over-quarter to $927B.
Based on T. Rowe Price Associates's 13F filing for Q4 2025, filed 17 Feb 2026.